Best Compounded GLP-1 Programs (2026)

Pharmacy partner is named, with a state license number

The single most important factor: the program tells you which pharmacy is preparing the medication, and that pharmacy holds a current license with the state board where it operates. Every state board of pharmacy in the U.S. publishes a public license lookup. A program that won't name its pharmacy partner is not a program we recommend. The same applies to 503B outsourcing facilities — those are FDA-registered and the registration is public.

Third-party testing certificates available

Reputable 503A pharmacies test every batch for sterility, identity, and potency. 503B outsourcing facilities are subject to current Good Manufacturing Practices and the testing is more rigorous. Better consumer programs make these certificates available on request — at minimum a Certificate of Analysis showing potency tested against the labeled concentration. Certificates that don't name the testing lab or that show generic ranges instead of specific values are red flags.

Clinically-justified individual prescription, not bulk-prep

Post-shortage compounding is supposed to be done against an individual patient prescription with a clinical justification, not as bulk preparation of the same formulation for everyone who signs up. Programs that offer one-size-fits-all formulations without genuine clinical individualization are operating in a legally murkier space than programs that show evidence of clinician-driven individualization (different concentrations, different titration schedules, different delivery formats).

Transparent pricing, no surprise add-ons

Better programs quote a single bundled price that includes the medication, consultation, syringes and supplies, sharps disposal, and shipping. Programs that quote a low monthly rate but charge separately for any of the above end up 15–20% more expensive at checkout. The first-month price you see on the homepage should match the first-month price you see at checkout.

Real clinician oversight, not a forwarding service

Every program on this list connects you with a board-certified prescribing clinician licensed in your state. The clinician — not an algorithm, not a sales rep — should be reviewing your intake, asking follow-up questions when warranted, and available for side-effect questions during therapy. Programs that hand off to the pharmacy immediately after a five-question form without any clinical interaction are not what licensed compounding looks like.

“Compounded semaglutide” on a checkout page is rarely just semaglutide. Most 503A pharmacies and several 503B outsourcing facilities offer combination formulations — the active GLP-1 plus an additional ingredient meant to address a specific side-effect profile or absorption pattern. Knowing what each one is helps you read the pharmacy's ingredient list intelligently.

• Semaglutide alone. The straight-line option. Same molecule as Ozempic / Wegovy in a pharmacy-determined concentration. Ask which carrier (saline, bacteriostatic water) is used.
• Semaglutide + cyanocobalamin (B12). The most common combination formulation. B12 is added at low dose; pharmacies cite better tolerance and a smoother titration. Clinically, B12 levels are not actually affected at these doses — the energy-uplift claim is anecdotal.
• Semaglutide + L-carnitine. Marketed for fat-oxidation support. The clinical evidence for additive weight-loss benefit is thin; the formulation is benign.
• Tirzepatide alone or tirzepatide + ondansetron. Tirzepatide causes more nausea than semaglutide for many patients. The ondansetron combination is used in some compounding programs to reduce first-dose nausea. Confirm the dose — too much ondansetron has its own side-effect profile.
• Retatrutide (compounded).Retatrutide is investigational and not FDA-approved at any dose. Compounding it in 2026 sits in legally murky territory. We don't recommend retatrutide compounded programs at this time.

Reputable programs disclose the full formulation on the intake form, name the pharmacy partner, and provide a Certificate of Analysis on request. Programs that hide the carrier ingredient or refuse to name the pharmacy are not in this guide.

When the FDA declared semaglutide off the shortage list in early 2025 and tirzepatide off in late 2024, a meaningful share of compounded GLP-1 commerce had to change. During the shortage, 503A pharmacies could prepare the molecule from bulk API at scale and against simplified prescriptions. Off the shortage list, that broad permission ended. What continues legally: clinician-led individual prescriptions for compounded preparations when there's a documented clinical justification — most often allergy or sensitivity to an inactive ingredient in the brand product, or a need for a non-standard dose or delivery format.

Reputable 503A pharmacies and 503B outsourcing facilities adapted their workflows. Reputable consumer-facing telehealth programs adapted their intake and clinical documentation. Programs that didn't adapt — programs that still operate as if the shortage was active — are at the highest risk of state board action and supply disruption. We've excluded those programs from this page.